Immunomodulation and Regenerative Capacity of MSCs for Long-COVID

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Nov 27

PMID 34830303

Citations 9

Authors

Xin Ya Loke

Siti A M Imran

Gee Jun Tye

Wan Safwani Wan Kamarul Zaman

Fazlina Nordin

Affiliations

Soon will be listed here.

Abstract

The rapid mutation of the SARS-CoV-2 virus is now a major concern with no effective drugs and treatments. The severity of the disease is linked to the induction of a cytokine storm that promotes extensive inflammation in the lung, leading to many acute lung injuries, pulmonary edema, and eventually death. Mesenchymal stem cells (MSCs) might prove to be a treatment option as they have immunomodulation and regenerative properties. Clinical trials utilizing MSCs in treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) have provided a basis in treating post-COVID-19 patients. In this review, we discussed the effects of MSCs as an immunomodulator to reduce the severity and death in patients with COVID-19, including the usage of MSCs as an alternative regenerative therapy in post-COVID-19 patients. This review also includes the current clinical trials in utilizing MSCs and their potential future utilization for long-COVID treatments.

Citing Articles

Multidisciplinary Management Strategies for Long COVID: A Narrative Review.

Prusinski C, Yan D, Klasova J, McVeigh K, Shah S, Fermo O Cureus. 2024; 16(5):e59478.

PMID: 38826995 PMC: 11142761. DOI: 10.7759/cureus.59478.

Mesenchymal Stem Cell-Based Therapies in the Post-Acute Neurological COVID Syndrome: Current Landscape and Opportunities.

Leon-Moreno L, Reza-Zaldivar E, Hernandez-Sapiens M, Villafana-Estarron E, Garcia-Martin M, Ojeda-Hernandez D Biomolecules. 2024; 14(1).

PMID: 38275749 PMC: 10813738. DOI: 10.3390/biom14010008.

Secretome of EMSCs neutralizes LPS‑induced acute lung injury via aerosol administration.

Tan J, Zhuo Z, Wang X, Zhang Y, Qian Y, Lin F Int J Mol Med. 2023; 52(5).

PMID: 37772372 PMC: 10558219. DOI: 10.3892/ijmm.2023.5307.

Equine Hoof Progenitor Cells Display Increased Mitochondrial Metabolism and Adaptive Potential to a Highly Pro-Inflammatory Microenvironment.

Pielok A, Kepska M, Steczkiewicz Z, Grobosz S, Bourebaba L, Marycz K Int J Mol Sci. 2023; 24(14).

PMID: 37511204 PMC: 10379971. DOI: 10.3390/ijms241411446.

Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment.

Fang Y, Lao P, Tang L, Chen J, Chen Y, Sun L Cell Transplant. 2023; 32:9636897231184611.

PMID: 37395459 PMC: 10328058. DOI: 10.1177/09636897231184611.

References

Ayala-Cuellar A, Kang J, Jeung E, Choi K . Roles of Mesenchymal Stem Cells in Tissue Regeneration and Immunomodulation. Biomol Ther (Seoul). 2018; 27(1):25-33. PMC: 6319543. DOI: 10.4062/biomolther.2017.260. View

Mallis P, Michalopoulos E, Chatzistamatiou T, Stavropoulos-Giokas C . Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection. World J Stem Cells. 2020; 12(8):731-751. PMC: 7477656. DOI: 10.4252/wjsc.v12.i8.731. View

Chen P, Lee N, Cia C, Ko W, Hsueh P . A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. Front Pharmacol. 2020; 11:584956. PMC: 7751753. DOI: 10.3389/fphar.2020.584956. View

Ullah M, Liu D, Thakor A . Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience. 2019; 15:421-438. PMC: 6529790. DOI: 10.1016/j.isci.2019.05.004. View

Lawson B, Gonzalez-Quintial R, Eleftheriadis T, Farrar M, Miller S, Sauer K . Interleukin-7 is required for CD4(+) T cell activation and autoimmune neuroinflammation. Clin Immunol. 2015; 161(2):260-9. PMC: 4658267. DOI: 10.1016/j.clim.2015.08.007. View

Meyerowitz E, Sen P, Schoenfeld S, Neilan T, Frigault M, Stone J . Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. Clin Infect Dis. 2020; 72(12):e1130-e1143. PMC: 7717185. DOI: 10.1093/cid/ciaa1759. View

Song N, Wakimoto H, Rossignoli F, Bhere D, Ciccocioppo R, Chen K . Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells. 2021; 39(6):707-722. PMC: 8014246. DOI: 10.1002/stem.3354. View

Fukui E, Funaki S, Kimura K, Momozane T, Kimura A, Chijimatsu R . Adipose Tissue-Derived Stem Cells Have the Ability to Differentiate into Alveolar Epithelial Cells and Ameliorate Lung Injury Caused by Elastase-Induced Emphysema in Mice. Stem Cells Int. 2019; 2019:5179172. PMC: 6590553. DOI: 10.1155/2019/5179172. View

Shiomi A, Usui T . Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm. 2015; 2015:568543. PMC: 4370199. DOI: 10.1155/2015/568543. View

10.

Nowakowski A, Walczak P, Lukomska B, Janowski M . Genetic Engineering of Mesenchymal Stem Cells to Induce Their Migration and Survival. Stem Cells Int. 2016; 2016:4956063. PMC: 4868914. DOI: 10.1155/2016/4956063. View

11.

Huang K, Su I, Theron M, Wu Y, Lai S, Liu C . An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2004; 75(2):185-94. PMC: 7166886. DOI: 10.1002/jmv.20255. View

12.

Son B, Marquez-Curtis L, Kucia M, Wysoczynski M, Turner A, Ratajczak J . Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells. 2006; 24(5):1254-64. DOI: 10.1634/stemcells.2005-0271. View

13.

Song P, Li W, Xie J, Hou Y, You C . Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020; 509:280-287. PMC: 7283076. DOI: 10.1016/j.cca.2020.06.017. View

14.

Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R . Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021; 6(1):58. PMC: 7873662. DOI: 10.1038/s41392-021-00488-5. View

15.

Kavianpour M, Saleh M, Verdi J . The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm. Stem Cell Res Ther. 2020; 11(1):404. PMC: 7499002. DOI: 10.1186/s13287-020-01849-7. View

16.

Lin P, Wang M, Wei Y, Kim T, Wei X . Coronavirus in human diseases: Mechanisms and advances in clinical treatment. MedComm (2020). 2020; 1(3):270-301. PMC: 7646666. DOI: 10.1002/mco2.26. View

17.

Fang S, Xu C, Zhang Y, Xue C, Yang C, Bi H . Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomal MicroRNAs Suppress Myofibroblast Differentiation by Inhibiting the Transforming Growth Factor-β/SMAD2 Pathway During Wound Healing. Stem Cells Transl Med. 2016; 5(10):1425-1439. PMC: 5031180. DOI: 10.5966/sctm.2015-0367. View

18.

Cronstein B . Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007; 65 Suppl 1:S11-5. View

19.

Gur-Wahnon D, Borovsky Z, Beyth S, Liebergall M, Rachmilewitz J . Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp Hematol. 2007; 35(3):426-33. DOI: 10.1016/j.exphem.2006.11.001. View

20.

Proal A, VanElzakker M . Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021; 12:698169. PMC: 8260991. DOI: 10.3389/fmicb.2021.698169. View